Abstract:Purpose: N 6 -methyladenosine (m 6 A) mRNA methylation is affected by dietary factors and associated with lipid metabolism; however, whether the regulatory role of resveratrol in lipid metabolism is involved in m 6 A mRNA methylation remains unknown. Here, the objective of this study was to investigate the effect of resveratrol on hepatic lipid metabolism and m 6 A RNA methylation in the liver of mice. Methods: A total of 24 male mice were randomly allocated to LFD (low-fat diet), LFDR (low-fat diet + resveratrol), HFD (high-fat diet), and HFDR (high-fat diet + resveratrol) groups for 12 weeks ( n = 6/group). Final body weight of mice was measured before sacrificing. Perirhemtric fat, abdominal and epididymal fat, liver tissues, and serum were collected at sacrifice and analyzed. Briefly, mice phenotype, lipid metabolic index, and m 6 A modification in the liver were assessed. Results: Compared to the HFD group, dietary resveratrol supplementation reduced the body weight and relative abdominal, epididymal, and perirhemtric fat weight in high-fat-exposed mice; however, resveratrol significantly increased average daily feed intake in mice given HFD. The amounts of serum low-density lipoprotein cholesterol (LDL), liver total cholesterol (TC), and triacylglycerol (TAG) were significantly decreased by resveratrol supplementation. In addition, resveratrol significantly enhanced the levels of peroxisome proliferator-activated receptor alpha ( PPARα ), peroxisome proliferator-activated receptor beta/delta ( PPARβ/δ ), cytochrome P450, family 4, subfamily a, polypeptide 10/14 ( CYP4A10 / 14 ), acyl-CoA oxidase 1 ( ACOX1 ), and fatty acid-binding protein 4 ( FABP4 ) mRNA and inhibited acyl-CoA carboxylase ( ACC ) mRNA levels in the liver. Furthermore, the resveratrol in HFD increased the transcript levels of methyltransferase like 3 ( METTL3 ), alkB homolog 5 ( ALKBH5 ), fat mass and obesity associated protein ( FTO ), and YTH domain family 2 ( YTHDF2 ), whereas it decreased the level of YTH domain family 3 ( YTHDF3 ) and m 6 A abundance in mice liver. Conclusion: The beneficial effect of resveratrol on lipid metabolism disorder under HFD may be due to decrease of m 6 A RNA methylation and increase of PPARα mRNA, providing mechanistic insights into the function of resveratrol in alleviating the disturbance of lipid metabolism in mice.

Resveratrol prevents hepatic steatosis and endoplasmic reticulum stress and regulates the expression of genes involved in lipid metabolism, insulin resistance, and inflammation in rats

Targeting the Gut Microbiota with Resveratrol: a Demonstration of Novel Evidence for the Management of Hepatic Steatosis.

The therapeutic effects of resveratrol on hepatic steatosis in high-fat diet-induced obese mice by improving oxidative stress, inflammation and lipid-related gene transcriptional expression

Resveratrol Prevents Suppression of Regulatory T-cell Production, Oxidative Stress, and Inflammation of Mice Prone or Resistant to High-Fat Diet–induced Obesity

Resveratrol Attenuates High-Fat Diet Induced Hepatic Lipid Homeostasis Disorder and Decreases m6A RNA Methylation

Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation

Resveratrol reduces the inflammatory response in adipose tissue and improves adipose insulin signaling in high-fat diet-fed mice.

Resveratrol Protects Against Nonalcoholic Fatty Liver Disease by Improving Lipid Metabolism and Redox Homeostasis Via the PPARα Pathway.

Resveratrol Inhibits the Formation and Accumulation of Lipid Droplets Through AdipoQ Signal Pathway and Lipid Metabolism Lncrnas

Resveratrol attenuates against high-fat-diet-promoted non-alcoholic fatty liver disease in rats mainly by targeting the miR-34a/SIRT1 axis

Effects of Resveratrol on Gut Microbiota and Fat Storage in A Mouse Model with High-Fat-Induced Obesity

Resveratrol prevents insulin resistance caused by short-term elevation of free fatty acids in vivo.

Resveratrol attenuates high-fat diet-induced insulin resistance by influencing skeletal muscle lipid transport and subsarcolemmal mitochondrial β-oxidation.

Resveratrol Improves High-Fat Induced Nonalcoholic Fatty Liver in Rats

Resveratrol Suppresses Hepatic Fatty Acid Synthesis and Increases Fatty Acid Β-Oxidation Via the Microrna-33/Sirt6 Signaling Pathway

Resveratrol inhibits white adipose deposition by the ESR1-mediated PI3K/AKT signaling pathway

Resveratrol Alleviates Hepatic Fibrosis in Associated with Decreased Endoplasmic Reticulum Stress-Mediated Apoptosis and Inflammation

Alleviative Effects of Resveratrol on Nonalcoholic Fatty Liver Disease Are Associated with Up Regulation of Hepatic Low Density Lipoprotein Receptor and Scavenger Receptor Class B Type I Gene Expressions in Rats

Resveratrol increases nephrin and podocin expression and alleviates renal damage in rats fed a high-fat diet.

Resveratrol Reduces Glucolipid Metabolic Dysfunction and Learning and Memory Impairment in a NAFLD Rat Model: Involvement in Regulating the Imbalance of Nesfatin-1 Abundance and Copine 6 Expression

Resveratrol Improves High-Fat Diet Induced Insulin Resistance by Rebalancing Subsarcolemmal Mitochondrial Oxidation and Antioxidantion